Presentation on theme: "Joel Kaiser Division of DMEPOS Policy Chronic Care Policy Group"— Presentation transcript:
1Inherent Reasonableness of Fee Schedule Amounts for Non-Mail Order Diabetic Testing Supplies Joel KaiserDivision of DMEPOS PolicyChronic Care Policy GroupCenter for Medicare
2Inherent Reasonableness (IR) Authority provided by section 1842(b)(8) of the Social Security Act (the Act) for adjusting grossly excessive or deficient Medicare fee schedule amountsBefore making a determination that a payment amount is not inherently reasonable by reason of its grossly excessive or deficient amount, CMS must consult with representatives of suppliers likely to be affected by the change in the payment amount
3Mandate for Competitive Bidding Section 1847(a)(2)(A) of the Act mandates competitive bidding programs for durable medical equipment (DME) and supplies used in conjunction with DME, such as test strips, lancets and other supplies used with home blood glucose monitors.The highest cost and highest volume items and services or those that have the largest savings potential must be phased in first under the program.
4Phased In Items and Services Competitive bidding programs have begun for:Oxygen and Oxygen Equipment (over $2 billion in annual allowed charges)Mail Order Diabetic Testing Supplies (over $1 billion)Wheelchairs (over $800 million)Continuous Positive Airway Pressure Devices and Respiratory Assist Devices (over $600 million)Enteral Nutrients, Supplies, and Equipment (over $500 million)Non-mail order diabetic testing supplies is last major category ($552 million in 2011) to be phased in
5Mail Order Diabetic Testing Supplies In 2011, 73% of total allowed services for diabetic testing supplies were identified on the claim form as furnished via mail order to the beneficiary’s home (HCPCS modifier KL). Total allowed charges for these supplies were $1,045,633,866.Contracts and national mail order payment amounts for diabetic testing supplies are scheduled to be implemented on July 1, The new mail order definition that includes all deliveries to the beneficiary and the anti-switching rule take effect at this time.
6Non-Mail Order Diabetic Testing Supplies Effective on July 1, 2013, only items that a beneficiary or caregiver picks up in person at a local pharmacy or storefront will be considered non-mail order supplies. The beneficiary or caregiver must leave the store with the supplies as all types of deliveries are considered mail order.Non-mail order diabetic testing supplies are the only DME items you must pick up in person.
7Competitive Bidding for Non-Mail Order Diabetic Testing Supplies Would involve awarding contracts to enough local pharmacies and storefronts capable of meeting demand for non-mail order supplies in each competitive bidding areaCould be as few as 5 local suppliers in an areaAll other local suppliers would be unable to receive payment for furnishing non-mail order supplies
8Price DiscrepancyThe single payment amounts for mail order diabetic testing strips (A4253) delivered in the nine local Round One Rebid competitive bidding areas range from $13.88 to $15.62.The national average fee schedule amount for non-mail order test strips is currently $37.67.The impact of this significant price discrepancy will be national in scope once the national mail order payment amounts take effect on July 1, 2013.
9Round One Recompete Product Categories On April 17, 2012, CMS announced the product categories for the Round One RecompeteA decision not to include non-mail order diabetic testing supplies was part of this announcement.This delay in phasing in these items was made in order to explore use of the IR authority to achieve mandated savings for these items, which would not involve local suppliers competing for contracts.
10The IR OptionCan potentially reduce the price discrepancy between mail order and non-mail order sooner than implementing competitive biddingAllows all enrolled suppliers, such as community pharmacies, to continue furnishing diabetic testing supplies to Medicare beneficiaries who prefer to pick up their supplies for various reasons, such as speaking with a pharmacist in person rather than over the phone
11Steps of the IR Process – 42 CFR 405.502(h) Impact Analysis – consider the potential impact of special payment limits on quality, access, beneficiary liability, assignment rates, and participation of suppliersSupplier Consultation – consult with representatives of suppliers likely to be affected by changes in payment amounts before making a determination that the amounts are not inherently reasonablePublication of National Limits – publish proposed and final notices in the Federal Register
12Publication of National Limits Proposed Notice:Explains the factors and data considered in determining that the payment amounts are grossly excessive or deficientSpecifies the proposed payment amountsExplains the factors and data considered in determining the payment amounts including the economic justification for a uniform payment limit, if it is proposedExplains the potential impacts of the payment limitsAllows no less than 60 days for public comments on the proposed payment limits
13Publication of National Limits Final Notice:Explains the factors and data consideredResponds to the public commentsEstablishes effective date for special payment limits
14Public CommentsPros and Cons of achieving mandated savings via competitive bidding or inherent reasonablenessSupplier consultation on whether the fee schedule amounts for non-mail order diabetic testing supplies are not inherently reasonableMandate to establish competitive bidding programs for non- mail order diabetic testing supplies is not eliminated by a decision not to pursue use of inherent reasonableness